Shiri Navon-Venezia1, Azita Leavitt, Yehuda Carmeli. 1. The Laboratory for Molecular Epidemiology and Antibiotic Research, Department of Epidemiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. shiri_nv@tasmc.health.gov.il
Abstract
OBJECTIVES: Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our hospital and worldwide, raising the necessity of finding effective therapies. We aimed to evaluate the in vitro activity of tigecycline against MDR A. baumannii clones isolated before tigecycline was used in our institution. METHODS: Eighty-two unique patient clinical isolates of multidrug-resistant A. baumannii collected in 2003 were studied. Species identification and antibiotic susceptibilities were determined by Vitek-2. Tigecycline MIC was determined by Etest. Clonal relatedness was determined by PFGE. RESULTS: MDR A. baumannii possessed 19 different pulsotypes. Sixty-six percent of the isolates were resistant to tigecycline, 12% were intermediate and 22% were susceptible. The MIC(50) and MIC(90) of tigecycline were 16 and 32 mg/L, respectively, with a wide MIC range of 1-128 mg/L. Variability in MIC of tigecycline was evident between and within the same pulsotype. CONCLUSIONS: We report here high resistance rates to tigecycline, and higher than previously described MICs, in multiple clones of MDR A. baumannii. As tigecycline represents a new treatment choice for infections caused by A. baumannii, these findings are worrisome.
OBJECTIVES: Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our hospital and worldwide, raising the necessity of finding effective therapies. We aimed to evaluate the in vitro activity of tigecycline against MDR A. baumannii clones isolated before tigecycline was used in our institution. METHODS: Eighty-two unique patient clinical isolates of multidrug-resistant A. baumannii collected in 2003 were studied. Species identification and antibiotic susceptibilities were determined by Vitek-2. Tigecycline MIC was determined by Etest. Clonal relatedness was determined by PFGE. RESULTS: MDR A. baumannii possessed 19 different pulsotypes. Sixty-six percent of the isolates were resistant to tigecycline, 12% were intermediate and 22% were susceptible. The MIC(50) and MIC(90) of tigecycline were 16 and 32 mg/L, respectively, with a wide MIC range of 1-128 mg/L. Variability in MIC of tigecycline was evident between and within the same pulsotype. CONCLUSIONS: We report here high resistance rates to tigecycline, and higher than previously described MICs, in multiple clones of MDR A. baumannii. As tigecycline represents a new treatment choice for infections caused by A. baumannii, these findings are worrisome.
Authors: Andrew Robinson; Anthony J Brzoska; Kylie M Turner; Ryan Withers; Elizabeth J Harry; Peter J Lewis; Nicholas E Dixon Journal: Microbiol Mol Biol Rev Date: 2010-06 Impact factor: 11.056
Authors: Ellen S Moland; David W Craft; Seong-geun Hong; Soo-young Kim; Lucas Hachmeister; Shimon D Sayed; Kenneth S Thomson Journal: Antimicrob Agents Chemother Date: 2008-06-02 Impact factor: 5.191
Authors: Michaelle Chojnacki; Xufeng Cao; Mikaeel Young; Rebecca N Fritz; Paul M Dunman; Daniel P Flaherty Journal: ChemMedChem Date: 2020-08-13 Impact factor: 3.466
Authors: Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova Journal: Haematologica Date: 2013-12 Impact factor: 9.941
Authors: Amanda G Oglesby-Sherrouse; Louise Djapgne; Angela T Nguyen; Adriana I Vasil; Michael L Vasil Journal: Pathog Dis Date: 2014-02-10 Impact factor: 3.166
Authors: Peng Wang; Sarah L Bowler; Serena F Kantz; Roberta T Mettus; Yan Guo; Christi L McElheny; Yohei Doi Journal: J Clin Microbiol Date: 2016-09-14 Impact factor: 5.948